Personalized Mechanical Ventilation Guided by UltraSound in Patients With Acute Respiratory Distress Syndrome

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Aug 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to help patients with Acute Respiratory Distress Syndrome (ARDS), a serious condition that affects breathing and can lead to death. The researchers want to see if using lung ultrasound (a safe and non-invasive imaging technique) to personalize mechanical ventilation—machines that help people breathe—can improve patient outcomes compared to standard ventilation methods. The goal is to reduce the number of patients who die within 90 days of treatment.

To participate in this trial, patients need to be between the ages of 65 and 90 and must be receiving mechanical ventilation in an intensive care unit for moderate or severe ARDS. However, there are some exclusions, such as patients under 18, those with certain other medical conditions, or anyone who has been on mechanical ventilation for too long recently. Participants can expect to receive personalized care based on ultrasound results, which could potentially lead to better recovery outcomes. It’s important to note that participation is voluntary, and informed consent will be required before joining the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admitted to a participating ICU,
• • invasively ventilated and
• • fulfil the Berlin criteria for moderate or severe ARDS.
• Exclusion Criteria:
• • Age under 18,
• • participation in other interventional studies with conflicting endpoints,
• • conditions in which LUS is not feasible or possible (e.g. subcutaneous emphysema, morbid obesity or wounds),
• • mechanical ventilation for longer than 7 consecutive days in the past 30 days,
• • history of ARDS in the previous month,
• • body-mass index higher than 40 kg/m²,
• • intracranial hypertension,
• • broncho-pleural fistula,
• • chronic respiratory diseases requiring long-term oxygen therapy or respiratory support,
• • pulmonary fibrosis with a vital capacity \< 50% (severe or very severe),
• • previously randomized in the PEGASUS study
• • ECMO
• • patients who are moribund or facing end of life and
• • no informed consent.